Published Date: 18 Oct 2024
Odds of undetectable PSA at 48 weeks doubled with addition of Pluvicto
Read Full NewsTest your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!
Here's some of what is coming soon to NeurologyLive® this week.
The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.
A gastroenterologist explains why treating bowel inflammation alone isn't enough to call inflammatory bowel disease "controlled."
David T. Rubin, MD, on the questions, screening tools, and system barriers standing between IBD care and the whole patient.
Weill Cornell investigator Iliyan D. Iliev, PhD, explains why fluconazole, not nystatin, cleared gut Candida in IBD.
LIBERTY: Prior Anti-Drug Antibodies Did Not Blunt SC Infliximab After Drug Holiday
1.
Nanoparticle vaccine prevents multiple cancers and stops metastasis in mice
2.
Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
Pulled Myeloma Drug Improves Survival in Trial
5.
First-Line Combo Therapies Best Chemo Alone in NSCLC Trials
1.
Emerging Therapies Using Immune-Reshaping Tumor Microenvironment Technologies
2.
Case-Based Learning: Persistent Neutropenia After Resolution of Infection
3.
Unlocking the Mysteries of Synovial Sarcoma: A New Hope for Treatment
4.
Best Clinical Practices in Hematology
5.
Digital Tumor-Board Collaboration Platforms: Transforming Multidisciplinary Cancer Care
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Recognizing Symptoms That May Require Cancer Evaluation
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
5.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation